The biopharmaceutical firm moves ahead with pulmonary disease research.
Biopharmaceutical company Kamada Ltd. (TASE: KMDA) has been granted a patent by the European Medicines Agency (EMEA) for its flagship product, Alpha-1 Antitrypsin (AAT), for the treatment of cystic fibrosis and bronchiectasis.
Kamada's share ended down 0.3% % on Thursday on the Tel Aviv Stock Exchange (TASE), and was up 1.6% in morning trading today.
Published by Globes [online], Israel business news - www.globes-online.com - on April 6, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008